MedPath

Evaluate the effect of Peganum Harmala on glycemic index in diabetic patient

Phase 3
Conditions
Type 2 diabetes.
Non-insulin-dependent diabetes mellitus
Registration Number
IRCT20170112031893N3
Lead Sponsor
Ghoum University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
60
Inclusion Criteria

type 2 diabetes over three year
age group40-75
Distal polyneuropathy resolutions based on questionnaires Michigan
HBA1C8% -10%

Exclusion Criteria

Kidney,liver,and heart failure based on the tests, history and physical exam
High blood pressure more than 180 mm Hg and advanced ;
diabetic Retinopathy
Pergnancy and lactation
History of amputation
Fever
the recent use of drugs for neuropathy {gabapentin , nortriptyline}
?Consumers of medicines that induce delayed gastric emptying such as: Acarbose, Miglitol, Exenatid, ?benzodiazepines, calcium channel blockers, narcotics, alpha-2 adrenergic receptor agonists such as ?clonidine, tricyclic antidepressants, dopamine agonists, cholinergic muscarinic receptor antagonists, ?Octreotide, phenothiazines, cyclosporine

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Fasting blood sugar. Timepoint: pre and early post-treatment. Method of measurement: Based on Labratory.
Secondary Outcome Measures
NameTimeMethod
Distal polyneuropathy. Timepoint: Before and 3 months after the intervention. Method of measurement: Michigan Questionnaire A.
© Copyright 2025. All Rights Reserved by MedPath